{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:39:12Z","timestamp":1790271552622,"version":"4.1.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"21","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T00:00:00Z","timestamp":1524009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.vaccine.2018.04.040","type":"journal-article","created":{"date-parts":[[2018,4,20]],"date-time":"2018-04-20T17:47:43Z","timestamp":1524246463000},"page":"2968-2972","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety, tolerability and immunogenicity of intramuscular administration of PRP-CRM197 Hib vaccine to healthy Japanese children: An open-label trial"],"prefix":"10.1016","volume":"36","author":[{"given":"Takehiro","family":"Togashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nodoka","family":"Mitsuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Sumino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Takanami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.04.040_b0005","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0140-6736(09)61203-4","article-title":"Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates","volume":"374","author":"Watt","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.04.040_b0010","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1473-3099(08)70152-X","article-title":"Haemophilus influenzae type b conjugate vaccine use and effectiveness","volume":"8","author":"Morris","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2018.04.040_b0015","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1097\/00006454-199809001-00005","article-title":"Haemophilus influenzae type b conjugate vaccines: a review of efficacy data","volume":"17","author":"Heath","year":"1998","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.04.040_b0020","unstructured":"Centers for disease control and prevention. Prevention and control of Haemophilus influenzae Type b Disease: recommendations of the advisory committee on immunization practices (ACIP). February 28, 2014\/63(RR01). p. 1\u201314."},{"key":"10.1016\/j.vaccine.2018.04.040_b0025","unstructured":"World Health Organization (WHO) WHO\/V&B. 00.05. Department of Vaccines and Biologicals; 2000."},{"key":"10.1016\/j.vaccine.2018.04.040_b0030","first-page":"413","article-title":"(WHO) position paper on Haemophilus influenzae type b conjugate vaccines","volume":"88","author":"World Health Organization","year":"2013","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2018.04.040_b0035","unstructured":"World Health Organization. Immunization, vaccines and biologicals - Haemophilus influenzae type b (Hib), http:\/\/www.who.int\/immunization\/monitoring_surveillance\/burden\/vpd\/surveillance_type\/sentinel\/Hib\/en\/ [accessed 23 November 2017]."},{"key":"10.1016\/j.vaccine.2018.04.040_b0040","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1186\/1471-2458-13-S3-S21","article-title":"The effect of Haemophilus influenzae type B and pneumococcal conjugate vaccines on childhood meningitis mortality: a systematic review","volume":"13","author":"Davis","year":"2013","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2018.04.040_b0045","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.clinthera.2011.11.027","article-title":"Two decades of experience with the Haemophilus influenzae serotype b conjugate vaccine in the United Kingdom","volume":"34","author":"Ladhani","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.vaccine.2018.04.040_b0050","unstructured":"Health and Labour Sciences Research Grants, Research on Regulatory Science of Pharmaceuticals and Medical Devices Study. Non-clinical and clinical investigations to test the efficacy, safety, and administration methods of the newly developed Hib, pneumococcal, HPV, and rotavirus vaccines. Research Report. 2014. http:\/\/mhlw-grants.niph.go.jp\/niph\/search\/NIDD02.do?resrchNum=201420046A [accessed 23 November 2017], in Japanese."},{"key":"10.1016\/j.vaccine.2018.04.040_b0055","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/infdis\/147.6.1100","article-title":"The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b","volume":"147","author":"K\u00e4yhty","year":"1983","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.04.040_b0060","first-page":"421","article-title":"Safety, tolerability and immunogenicity of a Haemophilus influenzae type b vaccine containing aluminum phosphate adjuvant administered at 2, 3 and 4 months of age","volume":"41","author":"Kanra","year":"1999","journal-title":"Turk J Pediatr"},{"key":"10.1016\/j.vaccine.2018.04.040_b0065","first-page":"43","article-title":"Safety and immunogenicity of two Haemophilus influenzae type b conjugate vaccines","volume":"94","author":"Matjila","year":"2004","journal-title":"S Afr Med J"},{"key":"10.1016\/j.vaccine.2018.04.040_b0070","first-page":"927","article-title":"A phase IV open label study to assess the safety, tolerability and immunogenicity of a Haemophilus influenzae type B (Hib) CRM197 conjugated vaccine administered to healthy infants at 2, 4, and 6 months of age","volume":"35","author":"Pancharoen","year":"2004","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"10.1016\/j.vaccine.2018.04.040_b0075","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/ijcp.12267","article-title":"Assessment of immunogenicity and safety following primary and booster immunisation with a CRM197-conjugated Haemophilus influenzae type b vaccine in healthy Chinese infants","volume":"67","author":"Jun","year":"2013","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.vaccine.2018.04.040_b0080","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1016\/j.vaccine.2016.05.050","article-title":"Immunogenicity and safety of a fully liquid aluminum phosphate adjuvanted Haemophilus influenzae type b PRP-CRM197-conjugate vaccine in healthy Japanese children: A phase III, randomized, observer-blind, multicenter, parallel-group study","volume":"34","author":"Togashi","year":"2016","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18305231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18305231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:25:32Z","timestamp":1759400732000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18305231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":16,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0264410X18305231"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.04.040","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, tolerability and immunogenicity of intramuscular administration of PRP-CRM197 Hib vaccine to healthy Japanese children: An open-label trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.04.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}